SUMMARY
Background The knowledge of clinically relevant markers distribution might become a useful tool in COVID-19 therapy using personalized approach in the lack of unified recommendations for COVID-19 patients management during pandemic. We aimed to identify the frequencies and distribution patterns of rs11385942 and rs657152 polymorphic markers, associated with severe COVID-19, among populations of the world, as well at the national level within Russia. The study was also dedicated to reveal whether population frequencies of both polymorphic markers are associated with COVID-19 cases, recovery and death rates.
Methods We genotyped 1883 samples from 91 ethnic populations from Russia and neighboring countries by rs11385942 and rs657152 markers. Local populations which were geographically close and genetically similar were pooled into 28 larger groups. In the similar way we compiled a dataset on the other regions of the globe using genotypes extracted or imputed from the available datasets (32 populations worldwide). The differences in alleles frequencies between groups were estimated and the frequency distribution geographic maps have been constructed. We run the correlation analysis of both markers frequencies in various populations with the COVID-19 epidemiological data on the same populations.
Findings The cartographic analysis revealed that distribution of rs11385942 follows the West Eurasian pattern: it is frequent in Europeans, West Asians, and particularly in South Asians but rare or absent in all other parts of the globe. Notably, there is no abrupt changes in frequency across Eurasia but the clinal variation instead. The distribution of rs657152 is more homogeneous. Higher population frequencies of both risk alleles correlated positively with the death rate. For the rs11385942 we can state the tendency only (r=0,13, p=0.65), while for rs657152 the correlation was significantly high (r=0,59, p=0,02). These reasonable correlations were obtained on the Russian dataset, but not on the world dataset.
Interpretation Using epidemiological statistics on Russia and neighboring countries we revealed the evident correlation of the risk alleles frequencies with the death rate from COVID-19. The lack of such correlations at the world level should be attributed to the differences in the ways epidemiological data have been counted in different countries. So that, we believe that genetic differences between populations make small but real contribution into the heterogeneity of the pandemic worldwide. New studies on the correlations between COVID-19 recovery/mortality rates and population’s gene pool are urgently needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ministry of Science and Education of the Russian Federation (State assignments for the Research Centre for Medical Genetics and Vavilov Institute of General Genetics) and by the Ministry of Health (State assignment for the Russian Medical Academy of Continuous Professional Education). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been performed in accordance with the Declaration of Helsinki and was approved by the Ethical Committee of the Research Centre for Medical Genetics, Moscow. Written informed consent was obtained from all sample donor.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Authors declare that all data provided in this manuscript is available and could be submitted on request.
